TransCon Treprostinil is being developed to treat pulmonary arterial hypertension.

Ascendis Pharma initiates TransCon Treprostinil Phase 1 research in healthy volunteers Ascendis Pharma A/S, a clinical stage biotechnology organization that applies its innovative TransCon technology to handle significant unmet medical needs, today announced that it has initiated a Stage 1 single ascending dosage study of TransCon Treprostinil in healthy volunteers. TransCon Treprostinil is being developed to treat pulmonary arterial hypertension, a life-threatening orphan disease seen as a elevated blood pressure in the pulmonary arteries. TransCon Treprostinil has been designed as an inert prodrug that enables a sustained launch of unmodified treprostinil in circulation carrying out a once-daily self-administered subcutaneous injection tadalafil-tablets.html .

Increasing the daily dosage past 75 mg did not reduce threat of cancer-related death, the study showed. And there are significant dangers to acquiring aspirin daily, such as for example bleeding and stroke. So what may be the take-away message? If somebody is taking low-dosage or regular aspirin it could put them at reduced risk for death from cancer, Dr. Alan Arslan, assistant professor of obstetrics and gynecology and environmental medicine at NY University Langone Medical Center, told CBS Information via email. 8 Cancer Red Flags Your Doc SHOULDN’T Ignore Do You Know What to Look For? You Should .. Aspirin Cuts Cancers Deaths, Study Shows An aspirin a day keeps the cancer apart.

Other Posts From Category "tomography":

Related Posts